The Respiratory Syncytial Virus (RSV) prophylactic population in the eight major markets (*8MM) is projected to increase from over 14.55 million cases in 2020 to 15.64 million in 2030, with an annual growth rate (AGR) of 0.75%, according to GlobalData, a leading data and analytics company.

The company’s latest report, ‘Respiratory Syncytial Virus (RSV): Epidemiology Forecast to 2030’, estimates that in 2030, the US will have the highest number of prophylactic eligible individuals across the 8MM, with over 6.53 million individuals. Spain will have the lowest number of prophylactic eligible individuals with approximately 0.66 million individuals.

In the *5EU, GlobalData estimates that in 2030 there to be over 6.32 million prophylactic eligible individuals, while Japan and Australia will have over 2.04 million and over 0.74 million prophylactic eligible individuals, respectively.

Walter Gabriel, MPH, Epidemiologist at GlobalData, comments: “The primary driver of change in the prophylactic population is the underlying demographics, specifically in the pediatric and elderly populations.”

While RSV currently does not have a known cure nor a vaccine, preventive measures can be taken to help mitigate the spread of infection. As such, understanding the prevalence of individuals who are at greatest risk of severe complications from RSV is critical to curbing exposure of the virus and administering prophylactic therapy to reduce the likelihood of severe RSV infection.

Gabriel concludes: “Although GlobalData epidemiologists do not expect any significant changes that would reduce the size of the prophylactic population, changes may always occur in the future with the development of new treatments for at-risk populations.”

*8MM: The US, France, Germany, Italy, Spain, the UK, Japan, and Australia

Out of the 8MM, the *5EU are: France, Germany, Italy, Spain, the UK